Says the man with the impossible to type name…
Says the man with the impossible to type name…
Most Popular
Sponsored
DAFNA trims IBB stake, but ETF's 27% annual return & 15.8% alpha show biotech strength.
EV stocks like RIVN & LCID show promise, but VFS's mounting losses ($11B since 2021) pose huge risk.
Broadcom leads AI ASICs with 60% share, locking in clients. Marvell faces competition, but both see huge revenue growth.
Invest $3K refund at 8% for 40 yrs: $65K+! Compounding fuels growth. Tax-advantaged accounts boost returns.
CRM down 23%, ADBE at 10.6x P/E. Both beaten-down tech stocks show upside potential amid AI shifts.
HGV's stake cut by 79.5K shares, value down $2.43M. Stock up 9.3% YTD, underperforming S&P 500.
HOG exec sells 4K shares amid -25% YTD drop. Stock at $18, well off highs. Revenue down 28%.
Sponsored
Must Read